Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Sirius Therapeutics today announced it has submitted an application in Australia…